RS100704A - Use of vasopeptidase inhibitors in the treatment of nephropathy - Google Patents

Use of vasopeptidase inhibitors in the treatment of nephropathy

Info

Publication number
RS100704A
RS100704A YUP100704A RS100704A RS 100704 A RS100704 A RS 100704A YU P100704 A YUP100704 A YU P100704A RS 100704 A RS100704 A RS 100704A
Authority
RS
Serbia
Prior art keywords
diabetic
nephropathy
treatment
vasopeptidase inhibitors
syndome
Prior art date
Application number
Other languages
English (en)
Inventor
Stefan Schafer
Wolfgang Linz
Markus Bleich
Jochen Huber
Original Assignee
Sanofi Aventis Deutschland Gmbh.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland Gmbh., filed Critical Sanofi Aventis Deutschland Gmbh.,
Publication of RS100704A publication Critical patent/RS100704A/sr
Publication of RS52478B publication Critical patent/RS52478B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Pronalazak opisuje upotrebu inhibitora vazopeptidaze formule (I) za tretman i/ili profilaksu nefropatije kod pacijenata sa dijabetesom ili bez dijabetesa, uključujući dijabetičnu ili ne-dijabetičnu nefropatiju, glomerulonefritis, glumerularnu sklerozu, nefrotični sindrom, hipertenzivnu nefrosklerozu, mikroalbuminouriju ili poslednji stadijum bolesti bubrega, ili rezistenciju na insulin ili metaboličke bolesti povezane sa endoproduktima uznapredovane glikolacije, kao što su dijabetične komplikacije, dijabetična neuropatija, dijabetična nefropatija, dijabetična retinopatija, katarakta, infarkt miokarda i/ili dijabetična kardiomiopatija ili ateroskleroza ili endotelijalna disfunkcija.
YUP100704 2002-06-28 2003-06-13 Upotreba inhibitora vazopeptidaze u tretmanu nefropatije RS52478B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2002129180 DE10229180A1 (de) 2002-06-28 2002-06-28 Verwendung von Vasopeptidase-Inhibitoren bei der Behandlung von metabolischen Erkrankungen, Nephropathie und mit AGE assoziierten Erkrankungen
PCT/EP2003/006276 WO2004002492A1 (en) 2002-06-28 2003-06-13 Use of vasopeptidase inhibitors in the treatment of nephropathy

Publications (2)

Publication Number Publication Date
RS100704A true RS100704A (en) 2007-02-05
RS52478B RS52478B (sr) 2013-02-28

Family

ID=29795983

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP100704 RS52478B (sr) 2002-06-28 2003-06-13 Upotreba inhibitora vazopeptidaze u tretmanu nefropatije

Country Status (39)

Country Link
US (2) US6930103B2 (sr)
EP (1) EP1519732B1 (sr)
JP (1) JP4564354B2 (sr)
KR (1) KR101072235B1 (sr)
CN (1) CN100366254C (sr)
AR (1) AR040343A1 (sr)
AT (1) ATE548040T1 (sr)
AU (1) AU2003280440B2 (sr)
BR (1) BR0312250A (sr)
CA (1) CA2490277C (sr)
CR (1) CR7667A (sr)
CY (1) CY1112905T1 (sr)
DE (1) DE10229180A1 (sr)
DK (1) DK1519732T3 (sr)
EC (1) ECSP045513A (sr)
ES (1) ES2383889T3 (sr)
HK (1) HK1079435A1 (sr)
HN (1) HN2003000193A (sr)
HR (1) HRP20041212B1 (sr)
IL (2) IL165935A0 (sr)
MA (1) MA27281A1 (sr)
MX (1) MXPA04012230A (sr)
NO (1) NO334811B1 (sr)
NZ (1) NZ537480A (sr)
OA (1) OA12871A (sr)
PA (1) PA8576501A1 (sr)
PE (1) PE20040582A1 (sr)
PL (1) PL218070B1 (sr)
PT (1) PT1519732E (sr)
RS (1) RS52478B (sr)
RU (1) RU2336080C2 (sr)
SI (1) SI1519732T1 (sr)
SV (1) SV2004001560A (sr)
TN (1) TNSN04262A1 (sr)
TW (1) TWI326215B (sr)
UA (1) UA82845C2 (sr)
UY (1) UY27869A1 (sr)
WO (1) WO2004002492A1 (sr)
ZA (1) ZA200409382B (sr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2482546C2 (ru) * 2011-04-28 2013-05-20 Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" Способ коррекции эндотелиальной дисфункции раствором гомеопатических разведений антител к с-концевому фрагменту рецептора ангиотензина ii

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5430145A (en) * 1990-10-18 1995-07-04 Merrell Dow Pharmaceuticals Inc. Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
CA2053340C (en) * 1990-10-18 2002-04-02 Timothy P. Burkholder Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
DE69211133T2 (de) * 1991-03-01 1996-10-31 Zeria Pharmaceutical Co., Ltd., Tokio/Tokyo Indan-derivate als thromboxan-antagonisten
CA2078758C (en) * 1991-09-27 2003-12-09 Alan M. Warshawsky 2-substituted indane-2-mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
DE69317764T2 (de) * 1992-02-14 1998-07-30 Merrell Pharmaceuticals Inc., Cincinnati, Ohio Aminoacetylmercaptoacetylamid derivate mit enkephalinase- und ace-hemmwirkung
US5484783A (en) * 1994-03-24 1996-01-16 Merrell Dow Pharmaceuticals Inc. Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic mercaptoacetylamide and benzazapine derivatives
JPH09510476A (ja) * 1994-03-24 1997-10-21 メリル・フアーマシユウテイカルズ・インコーポレイテツド 低コレステロール血性、抗アテローム性動脈硬化性および低トリグリセライド血性のアミノアセチルメルカプト誘導体
AU716519B2 (en) * 1995-06-30 2000-02-24 Laboratoires Merck Sharp & Dohme - Chibret Snc Method of treating renal disease using an ace inhibitor and an A II antagonist
EE03524B1 (et) 1995-12-27 2001-10-15 Yoshitomi Pharmaceutical Industries, Ltd. Vahend diabeedi komplikatsioonide profülaktikaks ja raviks
CA2382549C (en) * 1999-08-30 2005-03-15 Aventis Pharma Deutschland Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
US6149915A (en) 1999-09-29 2000-11-21 Shiva Biomedical, Llc Treatment of diabetic nephropathy and microalbuminuria
CZ299708B6 (cs) * 2001-04-12 2008-10-29 Sanofi - Aventis Deutschland GmbH Merkaptoacetylamidové deriváty, zpusob jejich prípravy a farmaceutické prostredky s jejich obsahem k ošetrování kardiovaskulárních onemocnení
AU2002355419A1 (en) * 2001-08-06 2003-02-24 Genomed, Llc Methods and compositions for treating diseases associated with excesses in ace

Also Published As

Publication number Publication date
HRP20041212A2 (en) 2005-06-30
DK1519732T3 (da) 2012-06-18
AU2003280440B2 (en) 2009-07-16
CN1665512A (zh) 2005-09-07
DE10229180A1 (de) 2004-01-29
MXPA04012230A (es) 2005-02-25
PA8576501A1 (es) 2004-02-07
NO334811B1 (no) 2014-06-02
CY1112905T1 (el) 2016-04-13
ECSP045513A (es) 2005-03-10
TWI326215B (en) 2010-06-21
MA27281A1 (fr) 2005-04-01
HRP20041212B1 (hr) 2013-06-30
OA12871A (en) 2006-09-15
IL165935A0 (en) 2006-01-15
CN100366254C (zh) 2008-02-06
BR0312250A (pt) 2005-04-26
TNSN04262A1 (en) 2007-03-12
JP2005533815A (ja) 2005-11-10
US20040058911A1 (en) 2004-03-25
RS52478B (sr) 2013-02-28
EP1519732B1 (en) 2012-03-07
CA2490277A1 (en) 2004-01-08
SI1519732T1 (sl) 2012-05-31
SV2004001560A (es) 2004-02-26
TW200406214A (en) 2004-05-01
KR101072235B1 (ko) 2011-10-12
CR7667A (es) 2005-06-16
ZA200409382B (en) 2006-01-25
PE20040582A1 (es) 2004-10-18
CA2490277C (en) 2011-11-01
UA82845C2 (en) 2008-05-26
KR20050013642A (ko) 2005-02-04
US6930103B2 (en) 2005-08-16
ES2383889T3 (es) 2012-06-27
HN2003000193A (es) 2004-10-27
ATE548040T1 (de) 2012-03-15
AU2003280440A1 (en) 2004-01-19
PL218070B1 (pl) 2014-10-31
US7514423B2 (en) 2009-04-07
JP4564354B2 (ja) 2010-10-20
EP1519732A1 (en) 2005-04-06
NZ537480A (en) 2005-11-25
AR040343A1 (es) 2005-03-30
PL372992A1 (en) 2005-08-08
US20050171090A1 (en) 2005-08-04
UY27869A1 (es) 2003-12-31
PT1519732E (pt) 2012-05-22
IL165935A (en) 2010-12-30
WO2004002492A1 (en) 2004-01-08
NO20050425L (no) 2005-01-25
RU2336080C2 (ru) 2008-10-20
HK1079435A1 (en) 2006-04-07
RU2005102087A (ru) 2005-07-10

Similar Documents

Publication Publication Date Title
EA011086B9 (ru) Производные пролина и их применение в качестве ингибиторов дипептидилпептидазы iv
AP2003002755A0 (en) Guanidinobenzamides as mc4-r agonists
IL186566A0 (en) Substituted 2-amin0alkylth10-benzimidaz0les and use thereof for reducing blood sugar levels
MA29795B1 (fr) Inhibiteurs de la dipeptidyl peptidase permetttant de traiter le diabete
MX2009012708A (es) Derivados de piridazinona.
MX2009005881A (es) Derivados de 2-(piperidin-4-il)-4-fenoxi o fenilamino-pirimidina como inhibidores de la transcriptasa inversa no nucleosida.
DE60224189D1 (de) Dipeptidylpeptidase-hemmer zur behandlung von diabetes
MY142252A (en) Pyrrolopyridine-based inhibitors of dipeptidyl peptidase iv and methods
DE602007007473D1 (en) 11-beta-hydroxysteroid-dehydrogenase-1-hemmer
JO3021B1 (ar) احادي هيدرات 4-[ 4-{[4- كلورو - 3- (ثلاثي فلورو ميثيل) فينيل ] كربامويل} امينو] -3- فلورو فينوكسي] -n- ميثيل بيريدين -2- كربوكساميد
NO20063794L (no) Tetrahydroisoquinolin- og tetrahydrobenzazepin-derivater som IGF-1R-inhibitorer
TW200633992A (en) Biaryloxymethylarenecarboxylic acids
MX2008009413A (es) Heterociclos como agonistas del receptor de acido nicotinico para el tratamiento de la dislipidemia.
WO2009134574A3 (en) Disubstituted phthalazine hedgehog pathway antagonists
MX2008013175A (es) Compuestos derivados de hidrazona de n-fenil-1,1,1-trifluorometasu lfonamida y su uso para controlar parasitos.
WO2007064753A3 (en) Cancer treatment method
CA2659376C (en) 2,4-diaminoquinazolines for spinal muscular atrophy
TW200407133A (en) Novel PPARα and PPARγ agonists
TW200730507A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
WO2004037776A3 (en) Novel compounds and their use as prar-modulators
MX2009009916A (es) Tetrahidroquinolinas sustituidas.
RS100704A (en) Use of vasopeptidase inhibitors in the treatment of nephropathy
ATE475642T1 (de) Phenoxyessigsäurederivate als ppar-agonisten
IL185807A0 (en) Use of amino-substituted benzimidazoles
TW200517111A (en) Glutamine fructose-6-phosphate amidotransferase (GFAT) inhibitors